In 2017, the Epidermolysis Bullosa market size in the seven major markets (i.e the United States, EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan) was USD 2,283.40 million, which is expected to increase during the forecast period.
Epidermolysis Bullosa is a cause of significant morbidity and mortality among the affected individuals. It is observed that Epidermolysis Bullosa affects around 1 in 30,000 to 50,000 people. In the seven major markets total Epidermolysis bullosa prevalent population was 41,509 in 2017.
Worldwide,several pharmaceutical and biotechnology companies such as Fibrocell Science, Castle Creek Pharmaceuticals, RegeneRx Biopharmaceuticals, Amryt Pharma, Abeona Therapeutics, Krystal Biotech, Shionogi, among others are diligently working towards the development of novel treatment therapies for Epidermolysis bullosa.
For more details, visit: https://www.delveinsight.com/blog/epidermolysis-bullosa-market/